Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial of TEW-7197 in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma (RRMM)

Trial Profile

A Phase I Trial of TEW-7197 in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma (RRMM)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pomalidomide (Primary) ; Vactosertib (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Nov 2019 Results (n=10; as of 30 July 2019) assessing safety and preliminary efficacy of combination of pomalidomide and vactosertib, released in 61st Annual Meeting and Exposition of the American Society of Hematology
    • 25 Apr 2019 Planned End Date changed from 1 May 2019 to 1 Dec 2019.
    • 25 Apr 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top